HEALTH TECHNOLOGY ASSESSMENT FOR DECISION MAKERS

July 14–16, 2014 • Dalhousie University

AN INTENSIVE COURSE ON PRAGMATIC HTA TOOLS FOR DECISION MAKERS, INDUSTRY REPRESENTATIVES, AND RESEARCHERS.
WHO SHOULD TAKE THIS COURSE?

- Individuals who use HTA to make decisions relating to drugs, devices, and programs
- Decision-makers, practitioners, and researchers who would like to be able to use HTA concepts and methods

KEY FEATURES

- Intensive three-day program
- Theory bursts in lecture format to introduce and explain key concepts
- Interactive sessions (small group learning and computer labs) to explore illustrative cases

OBJECTIVES

By the end of the course, participants will be able to review and assess:

- Measures of clinical evidence
- Cost-effectiveness analyses
- Approaches to integrating social and ethical issues

DATE & LOCATION

**Date:** July 14–16, 2014  
**Location:** Dalhousie University  
Student Union Building, 3rd floor  
6136 University Avenue  
Halifax, NS B3H 4J2

REGISTRATION & FEE

**Registration Deadline:** July 9, 2014

**Course Fee (Publicly Funded Organizations):** $300 CDN  
**Course Fee (Industry & Consultants):** $1200 CDN

The course fee includes tuition fee, all study materials, and food (breakfast, break refreshments and lunch for three days, and the Tuesday social/dinner).

**Registration:** You can register online or send a printed online form via mail (for cheque payments only).

http://www.ihpme.utoronto.ca/about/conted/hti2014/feereg.htm

**Payment:** You can pay online with your credit card or pay with a cheque made payable to the ‘University of Toronto.’

http://www.ihpme.utoronto.ca/about/conted/hti2014/feereg/HTI-moneris.htm
Day 1: Clinical Evidence

Day 1 will examine the nature of clinical evidence. Participants will learn the strengths and weaknesses of alternative study designs such as randomized controlled trials and observational research and understand how evidence strength is graded. We will also review common measures of effectiveness used in the medical literature so participants can understand the outcomes that are commonly reported in health technology assessments.

Day 2: Economic Evidence

Day 2 will explore the idea of value - the relationship between cost and health benefit. Participants will learn the key concepts and designs in cost effectiveness analysis, how to perform a simple analysis, and how to appraise and interpret cost effectiveness analyses that are part of health technology assessments.

Day 3: Social and Ethical Issues

Day 3 will explore the social and ethical issues arising in the assessment of health technologies - why these issues are important and how they can be addressed. Participants will be introduced to methods for assessing stakeholder values and preferences through research evidence or stakeholder engagement, approaches to integrating ethics and social values considerations into HTA assessments, and the decision-making and appeal processes that can improve the fairness and legitimacy of HTA decisions.

For detailed course descriptions, please visit [http://theta.utoronto.ca/HTAI](http://theta.utoronto.ca/HTAI)
FACULTY

The Institute features leading HTA faculty from Institute of Health Policy, Management & Evaluation and other departments at the University of Toronto. This year, the Institute will feature faculty from the Department of Community Health and Epidemiology and Maritime SPOR SUPPORT Unit at Dalhousie University.

James Brophy, MD, PhD  
Professor, Department of Medicine, Epidemiology and Biostatistics, McGill University; Staff Physician, Division of Cardiology, McGill University Health Centre

Leslie Campbell, PhD (c)  
Maritime SPOR Support Unit (MSSU)

Judith Fisher, PhD  
Manager, Drug Technology Assessment, Pharmaceutical Services, Nova Scotia Department of Health and Wellness

Jennifer Gibson, PhD  
Sun Life Financial Chair in Bioethics; Director, Joint Centre for Bioethics; Director, World Health Organization Collaborating Centre for Bioethics; Associate Professor, Institute of Health Policy, Management & Evaluation, University of Toronto

Murray Krahn, MD, MSc  
F. Norman Hughes Chair in Pharmacoeconomics, University of Toronto; Director, Toronto Health Economics and Technology Assessment Collaborative (THETA); Member, Ontario Health Technology Advisory Committee

Lynn Lethbridge, MA  
Research Project Manager, Maritime SPOR Support Unit (MSSU)

Adrian Levy, PhD  
Professor and Head, Department of Community Health and Epidemiology, Dalhousie University; District Chief, Capital District Health Authority; Executive Director, Maritime SPOR SUPPORT Unit (MSSU)

Fiona Miller, PhD  
Associate Professor, Institute of Health Policy, Management and Evaluation, University of Toronto

Brian O'Rourke, PharmD  
President and Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health (CADTH)

Petros Pechlivanglou, PhD  
Health Economist, Toronto Health Economics and Technology Assessment Collaborative, University of Toronto

Valeria Rac, MD, PhD  
Associate Program Director and Director Clinical Research Division, Toronto Health Economics and Technology Assessment Collaborative; Assistant Professor, Leslie Dan Faculty of Pharmacy and Institute of Health Policy, Management & Evaluation, University of Toronto

Prakesh Shah, MD, MSc, MBBS, DCH, MRCP, FRCP  
Associate Professor, Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto

Chris Skedgel, PhD  
Senior Policy & Outcomes Researcher, Maritime SPOR Support Unit (MSSU); Research Health Economist, Atlantic Clinical Cancer Research Unit (ACCRU)

For a full faculty listing, please visit http://theta.utoronto.ca/HTAI.

CONTACT INFORMATION

For more information, please contact:

Anne Louise Pontigon Montgomery  |  p. 416-978-2067  |  e. annelouise.pontigon@utoronto.ca
Marsha M. Bennett  |  p. 902-473-7640  |  e. marsham.bennett@cdha.nshealth.ca

http://theta.utoronto.ca/HTAI